Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study
Open Access
- 18 September 2023
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (10) , 1541-1552
Abstract
This study aimed to characterize apixaban pharmacokinetics (PKs) and its variability in a real‐world clinical setting of hospitalized patients using a population PK (PopPK) approach. Model‐based simulations helped to identify factors that affect apixaban exposure and their clinical significance. A classic stepwise strategy was applied to determine the best PopPK model for describing typical apixaban PKs in hospitalized patients from the OptimAT study (n = 100) and evaluating the associated variability and influencing factors. Apixaban exposure under specific conditions was assessed using the final model. A two‐compartment model with first‐order absorption and elimination best described the data. The developed PopPK model revealed a major role of renal function and a minor role of P‐glycoprotein phenotypic (P‐gp) activity in explaining apixaban variability. The final model indicated that a patient with stage 4 chronic kidney disease (creatinine clearance [CLcr] = 15–29 mL/min) would have a 45% higher drug exposure than a patient with normal renal function (CLcr >90 mL/min), with a further 12% increase if the patient was also a poor metabolizer of P‐gp. A high interindividual variability in apixaban PKs was observed in a real‐life setting, which was partially explained by renal function and by P‐gp phenotypic activity. Target apixaban concentrations are reached under standard dosage regimens, but overexposure can rapidly occur in the presence of cumulative factors warranting the development of a predictive tool for tailoring apixaban exposure and its clinical utility in at‐risk patients.Keywords
This publication has 42 references indexed in Scilit:
- Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and ApixabanCanadian Journal of Cardiology, 2013
- Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Practical management of patients on apixaban: a consensus guideThrombosis Journal, 2013
- Apixaban in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction StudiesDrug Metabolism and Disposition, 2010
- Apixaban Metabolism and Pharmacokinetics after Oral Administration to HumansDrug Metabolism and Disposition, 2009
- Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesJournal of Thrombosis and Haemostasis, 2008
- Age‐related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applicationsBritish Journal of Clinical Pharmacology, 2003
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981